Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Hyperimmune Globulins Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Global Hyperimmune Globulins Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Industry: Pharma & Healthcare

Published Date: 2025-03-28

Pages: 141 Pages

Report ld: 4674441

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Hyperimmune Globulins Market Size(US$)

CAGR 2025-2031

Market Size,2031

USD 3,089

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 2,058 million

Market Forecast in 2031(Value)

US$ 3,089 million

CAGR

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

In 2024, the global market size of Hyperimmune Globulins was estimated to be worth US$ 1936 million and is forecast to reach approximately US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%. Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent. In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.

The hyperimmune globulin market is primarily driven by the increasing prevalence of infectious diseases and the rising demand for immunoglobulin therapies. These therapies are crucial in treating immunodeficiency disorders and providing passive immunity against various pathogens, which fuels market growth. Additionally, advancements in plasma-derived therapies and increasing government initiatives for immunization programs contribute to market expansion.

However, the market faces significant challenges, such as the high cost of treatment and limited availability of plasma, which is a critical raw material for hyperimmune globulin production. Moreover, stringent regulatory requirements for product approval and potential side effects associated with immunoglobulin therapies can hinder market growth.

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Hyperimmune Globulins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperimmune Globulins.

The Hyperimmune Globulins market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hyperimmune Globulins manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.

By Company

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Segment by Type

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Herpes Zoster Immune Globulin

Other

Segment by Application

Government Institutions

Private Sector

Other

By Region

North America

United States

Canada

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Australia

Rest of Asia-Pacific

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Rest of Europe

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Hyperimmune Globulins in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 3: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hyperimmune Globulins sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.

Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.

Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.

Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.

Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.

Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: Research Findings and Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Hyperimmune Globulins Product Introduction

1.2 Market by Type

1.2.1 Global Hyperimmune Globulins Market Size Growth Rate by Type (2020 VS 2024 VS 2031)

1.2.2 Hepatitis B Immunoglobulins

1.2.3 Rabies Immunoglobulins

1.2.4 Tetanus Immunoglobulins

1.2.5 Rho(D) Immunoglobulins

1.2.6 Herpes Zoster Immune Globulin

1.2.7 Other

1.3 Market by Application

1.3.1 Global Hyperimmune Globulins Market Size Growth Rate by Application (2020 VS 2024 VS 2031)

1.3.2 Government Institutions

1.3.3 Private Sector

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Hyperimmune Globulins Market Size Estimates and Forecasts

2.1.1 Global Hyperimmune Globulins Revenue 2020-2031

2.1.2 Global Hyperimmune Globulins Sales 2020-2031

2.2 Hyperimmune Globulins Market Size by Region: 2024 Versus 2031

2.3 Hyperimmune Globulins Sales by Region (2020-2031)

2.3.1 Global Hyperimmune Globulins Sales by Region: 2020-2025

2.3.2 Global Hyperimmune Globulins Sales Forecast by Region (2026-2031)

2.3.3 Global Hyperimmune Globulins Sales Market Share by Region (2020-2031)

2.4 Hyperimmune Globulins Market Estimates and Projections by Region (2026-2031)

2.4.1 Global Hyperimmune Globulins Revenue by Region: 2020-2025

2.4.2 Global Hyperimmune Globulins Revenue Forecast by Region (2026-2031)

2.4.3 Global Hyperimmune Globulins Revenue Market Share by Region (2020-2031)

3 Market Segments

3.1 Breakdown Data by Type

3.1.1 Global Hyperimmune Globulins Sales by Type (2020-2031)

3.1.1.1 Global Hyperimmune Globulins Sales Volume by Type (2020-2031)

3.1.1.2 Global Hyperimmune Globulins Sales Market Share by Type (2020-2031)

3.1.2 Global Hyperimmune Globulins Revenue by Type (2020-2031)

3.1.2.1 Global Hyperimmune Globulins Revenue by Type (2020-2031)

3.1.2.2 Global Hyperimmune Globulins Revenue Market Share by Type (2020-2031)

3.1.3 Hyperimmune Globulins Average Selling Price (ASP) by Type (2020-2031)

3.2 Breakdown Data by Application

3.2.1 Global Hyperimmune Globulins Sales by Application (2020-2031)

3.2.1.1 Global Hyperimmune Globulins Sales Volume by Application (2020-2031)

3.2.1.2 Global Hyperimmune Globulins Sales Market Share by Application (2020-2031)

3.2.2 Global Hyperimmune Globulins Revenue by Application (2020-2031)

3.2.2.1 Global Hyperimmune Globulins Revenue by Application (2020-2031)

3.2.2.2 Global Hyperimmune Globulins Revenue Market Share by Application (2020-2031)

3.2.3 Hyperimmune Globulins Average Selling Price (ASP) by Application (2020-2031)

3.3 by Type and by Application Crossing Analysis

3.3.1 Hepatitis B Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application

3.3.2 Rabies Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application

3.3.3 Tetanus Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application

3.3.4 Rho(D) Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application

3.3.5 Herpes Zoster Immune Globulin of Hyperimmune Globulins Revenue Market Share by Application

3.3.6 Other of Hyperimmune Globulins Revenue Market Share by Application

4 Global Hyperimmune Globulins by Manufacturers

4.1 Global Top Hyperimmune Globulins Manufacturers by Sales (2020-2025)

4.1.1 Global Hyperimmune Globulins Sales by Manufacturer (2020-2025)

4.1.2 Global Hyperimmune Globulins Sales Market Share by Manufacturer (2020-2025)

4.2 Global Top Hyperimmune Globulins Manufacturers by Revenue (2020-2025)

4.2.1 Global Hyperimmune Globulins Revenue by Manufacturer (2020-2025)

4.2.2 Global Hyperimmune Globulins Revenue Share by Manufacturer (2020-2025)

4.3 Global Hyperimmune Globulins Price by Manufacturer (2020-2025)

4.4 Competitive Landscape

4.4.1 Key Hyperimmune Globulins Manufacturers Covered: Ranking by Revenue

4.4.2 Global Hyperimmune Globulins Market Concentration Ratio (CR5 and HHI) & (2020-2025)

4.4.3 Global Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

4.5 Global Hyperimmune Globulins Manufacturing Base Distribution, Product Type

4.5.1 Hyperimmune Globulins Manufacturers Manufacturing Base Distribution, Headquarters

4.5.2 Date of International Manufacturers Enter into Hyperimmune Globulins Market

4.5.3 Manufacturers Hyperimmune Globulins Product Type and Application

4.5.4 Hepatitis B Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer

4.5.5 Rabies Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer

4.5.6 Tetanus Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer

4.5.7 Rho(D) Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer

4.5.8 Herpes Zoster Immune Globulin Market Sales of Hyperimmune Globulins by Manufacturer

4.5.9 Other Market Sales of Hyperimmune Globulins by Manufacturer

4.6 Manufacturers Mergers & Acquisitions, Expansion Plans

5 Company Profiles

5.1 CSL Behring

5.1.1 CSL Behring Company Information

5.1.2 CSL Behring Description, Business Overview

5.1.3 CSL Behring Hyperimmune Globulins Products Offered

5.1.4 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.1.5 CSL Behring Hyperimmune Globulins Sales by Product in 2024

5.1.6 CSL Behring Hyperimmune Globulins Sales by Application in 2024

5.1.7 CSL Behring Hyperimmune Globulins Sales by Geographic Area in 2024

5.1.8 CSL Behring Recent Developments

5.2 Grifols

5.2.1 Grifols Company Information

5.2.2 Grifols Description, Business Overview

5.2.3 Grifols Hyperimmune Globulins Products Offered

5.2.4 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.2.5 Grifols Hyperimmune Globulins Sales by Product in 2024

5.2.6 Grifols Hyperimmune Globulins Sales by Application in 2024

5.2.7 Grifols Hyperimmune Globulins Sales by Geographic Area in 2024

5.2.8 Grifols Recent Developments

5.3 Biotest

5.3.1 Biotest Company Information

5.3.2 Biotest Description, Business Overview

5.3.3 Biotest Hyperimmune Globulins Products Offered

5.3.4 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.3.5 Biotest Hyperimmune Globulins Sales by Product in 2024

5.3.6 Biotest Hyperimmune Globulins Sales by Application in 2024

5.3.7 Biotest Hyperimmune Globulins Sales by Geographic Area in 2024

5.3.8 Biotest Recent Developments

5.4 Kedrion

5.4.1 Kedrion Company Information

5.4.2 Kedrion Description, Business Overview

5.4.3 Kedrion Hyperimmune Globulins Products Offered

5.4.4 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.4.5 Kedrion Hyperimmune Globulins Sales by Product in 2024

5.4.6 Kedrion Hyperimmune Globulins Sales by Application in 2024

5.4.7 Kedrion Hyperimmune Globulins Sales by Geographic Area in 2024

5.4.8 Kedrion Recent Developments

5.5 CBPO

5.5.1 CBPO Company Information

5.5.2 CBPO Description, Business Overview

5.5.3 CBPO Hyperimmune Globulins Products Offered

5.5.4 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.5.5 CBPO Hyperimmune Globulins Sales by Product in 2024

5.5.6 CBPO Hyperimmune Globulins Sales by Application in 2024

5.5.7 CBPO Hyperimmune Globulins Sales by Geographic Area in 2024

5.5.8 CBPO Recent Developments

5.6 Emergent (Cangene)

5.6.1 Emergent (Cangene) Company Information

5.6.2 Emergent (Cangene) Description, Business Overview

5.6.3 Emergent (Cangene) Hyperimmune Globulins Products Offered

5.6.4 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.6.5 Emergent (Cangene) Hyperimmune Globulins Sales by Product in 2024

5.6.6 Emergent (Cangene) Hyperimmune Globulins Sales by Application in 2024

5.6.7 Emergent (Cangene) Hyperimmune Globulins Sales by Geographic Area in 2024

5.6.8 Emergent (Cangene) Recent Developments

5.7 Kamada

5.7.1 Kamada Company Information

5.7.2 Kamada Description, Business Overview

5.7.3 Kamada Hyperimmune Globulins Products Offered

5.7.4 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.7.5 Kamada Hyperimmune Globulins Sales by Product in 2024

5.7.6 Kamada Hyperimmune Globulins Sales by Application in 2024

5.7.7 Kamada Hyperimmune Globulins Sales by Geographic Area in 2024

5.7.8 Kamada Recent Developments

5.8 CNBG

5.8.1 CNBG Company Information

5.8.2 CNBG Description, Business Overview

5.8.3 CNBG Hyperimmune Globulins Products Offered

5.8.4 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.8.5 CNBG Hyperimmune Globulins Sales by Product in 2024

5.8.6 CNBG Hyperimmune Globulins Sales by Application in 2024

5.8.7 CNBG Hyperimmune Globulins Sales by Geographic Area in 2024

5.8.8 CNBG Recent Developments

5.9 Hualan Bio

5.9.1 Hualan Bio Company Information

5.9.2 Hualan Bio Description, Business Overview

5.9.3 Hualan Bio Hyperimmune Globulins Products Offered

5.9.4 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.9.5 Hualan Bio Hyperimmune Globulins Sales by Product in 2024

5.9.6 Hualan Bio Hyperimmune Globulins Sales by Application in 2024

5.9.7 Hualan Bio Hyperimmune Globulins Sales by Geographic Area in 2024

5.9.8 Hualan Bio Recent Developments

5.10 Shanghai RAAS

5.10.1 Shanghai RAAS Company Information

5.10.2 Shanghai RAAS Description, Business Overview

5.10.3 Shanghai RAAS Hyperimmune Globulins Products Offered

5.10.4 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.10.5 Shanghai RAAS Hyperimmune Globulins Sales by Product in 2024

5.10.6 Shanghai RAAS Hyperimmune Globulins Sales by Application in 2024

5.10.7 Shanghai RAAS Hyperimmune Globulins Sales by Geographic Area in 2024

5.10.8 Shanghai RAAS Recent Developments

5.11 Sichuan Yuanda Shuyang

5.11.1 Sichuan Yuanda Shuyang Company Information

5.11.2 Sichuan Yuanda Shuyang Description, Business Overview

5.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Products Offered

5.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.11.5 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Product in 2024

5.11.6 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Application in 2024

5.11.7 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Geographic Area in 2024

5.11.8 Sichuan Yuanda Shuyang Recent Developments

5.12 ADMA Biologics

5.12.1 ADMA Biologics Company Information

5.12.2 ADMA Biologics Description, Business Overview

5.12.3 ADMA Biologics Hyperimmune Globulins Products Offered

5.12.4 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

5.12.5 ADMA Biologics Hyperimmune Globulins Sales by Product in 2024

5.12.6 ADMA Biologics Hyperimmune Globulins Sales by Application in 2024

5.12.7 ADMA Biologics Hyperimmune Globulins Sales by Geographic Area in 2024

5.12.8 ADMA Biologics Recent Developments

6 North America

6.1 North America Hyperimmune Globulins Market Size YoY Growth 2020-2031

6.2 North America Hyperimmune Globulins Market Facts & Figures by Country

6.2.1 North America Hyperimmune Globulins Sales by Country (2020-2031)

6.2.2 North America Hyperimmune Globulins Revenue by Country (2020-2031)

6.3 North America Hyperimmune Globulins Sales by Type (2020-2025)

6.4 North America Hyperimmune Globulins Sales by Application (2020-2025)

7 Asia-Pacific

7.1 Asia-Pacific Hyperimmune Globulins Market Size YoY Growth 2020-2031

7.2 Asia-Pacific Hyperimmune Globulins Market Facts & Figures by Region

7.2.1 Asia-Pacific Hyperimmune Globulins Sales by Region (2020-2031)

7.2.2 Asia-Pacific Hyperimmune Globulins Revenue by Region (2020-2031)

7.3 Asia-Pacific Hyperimmune Globulins Sales by Type (2020-2025)

7.4 Asia-Pacific Hyperimmune Globulins Sales by Application (2020-2025)

8 Europe

8.1 Europe Hyperimmune Globulins Market Size YoY Growth 2020-2031

8.2 Europe Hyperimmune Globulins Market Facts & Figures by Country

8.2.1 Europe Hyperimmune Globulins Sales by Country (2020-2031)

8.2.2 Europe Hyperimmune Globulins Revenue by Country (2020-2031)

8.3 Europe Hyperimmune Globulins Sales by Type (2020-2025)

8.4 Europe Hyperimmune Globulins Sales by Application (2020-2025)

9 Latin America

9.1 Latin America Hyperimmune Globulins Market Size YoY Growth 2020-2031

9.2 Latin America Hyperimmune Globulins Market Facts & Figures by Country

9.2.1 Latin America Hyperimmune Globulins Sales by Country (2020-2031)

9.2.2 Latin America Hyperimmune Globulins Revenue by Country (2020-2031)

9.3 Latin America Hyperimmune Globulins Sales by Type (2020-2025)

9.4 Latin America Hyperimmune Globulins Sales by Application (2020-2025)

10 Middle East and Africa

10.1 Latin America Hyperimmune Globulins Market Size YoY Growth 2020-2031

10.2 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country

10.2.1 Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2031)

10.2.2 Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2031)

10.3 Middle East and Africa Hyperimmune Globulins Sales by Type (2020-2025)

10.4 Middle East and Africa Hyperimmune Globulins Sales by Application (2020-2025)

11 Supply Chain and Sales Channel analysis

11.1 Hyperimmune Globulins Supply Chain Analysis

11.2 Hyperimmune Globulins Key Raw Materials and Upstream Suppliers

11.3 Hyperimmune Globulins Clients Analysis

11.4 Hyperimmune Globulins Sales Channel and Sales Model Analysis

11.4.1 Hyperimmune Globulins Distribution Channel Analysis: Indirect Sales VS Direct Sales

11.4.2 Hyperimmune Globulins Distribution Channel Analysis: Online Sales VS Offline Sales

11.4.3 Hyperimmune Globulins Distributors

12 Hyperimmune Globulins Market Dynamics

12.1 Hyperimmune Globulins Industry Trends

12.2 Hyperimmune Globulins Market Drivers

12.3 Hyperimmune Globulins Market Challenges

12.4 Hyperimmune Globulins Market Restraints

13 Research Findings and Conclusion

14 Appendix

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.1.1 Research Programs/Design

14.1.1.2 Market Size Estimation

14.1.1.3 Market Breakdown and Data Triangulation

14.1.2 Data Source

14.1.2.1 Secondary Sources

14.1.2.2 Primary Sources

14.2 Author Details

14.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Hyperimmune Globulins Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Hyperimmune Globulins Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2024 VS 2031

Table 4. Global Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)

Table 5. Global Hyperimmune Globulins Sales Forecast by Region (2026-2031) & (K Units)

Table 6. Global Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)

Table 7. Global Hyperimmune Globulins Revenue Forecast by Region (2026-2031) & (US$ Million)

Table 8. Global Hyperimmune Globulins Sales Volume by Type (2020-2025) & (K Units)

Table 9. Global Hyperimmune Globulins Sales Volume by Type (2026-2031) & (K Units)

Table 10. Global Hyperimmune Globulins Revenue by Type (2020-2025) & (US$ Million)

Table 11. Global Hyperimmune Globulins Revenue Forecast by Type (2026-2031) & (US$ Million)

Table 12. Global Hyperimmune Globulins Sales Volume by Application (2020-2025) & (K Units)

Table 13. Global Hyperimmune Globulins Sales Volume by Application (2026-2031) & (K Units)

Table 14. Global Hyperimmune Globulins Revenue by Application (2020-2025) & (US$ Million)

Table 15. Global Hyperimmune Globulins Revenue by Application (2026-2031) & (US$ Million)

Table 16. Global Hyperimmune Globulins Sales by Manufacturer (2020-2025) & (K Units)

Table 17. Global Hyperimmune Globulins Sales Share by Manufacturer (2020-2025)

Table 18. Hyperimmune Globulins Revenue by Manufacturer (2020-2025) & (US$ Million)

Table 19. Hyperimmune Globulins Revenue Share by Manufacturer (2020-2025)

Table 20. Key Manufacturers Hyperimmune Globulins Price (2020-2025) & (USD/Unit)

Table 21. Ranking of Global Top Hyperimmune Globulins Manufacturers by Revenue (US$ Million) in 2024

Table 22. Global Hyperimmune Globulins Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)

Table 23. Global Hyperimmune Globulins by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperimmune Globulins as of 2024)

Table 24. Hyperimmune Globulins Manufacturers Manufacturing Base Distribution and Headquarters

Table 25. Date of International Manufacturers Enter into Hyperimmune Globulins Market

Table 26. Manufacturers Hyperimmune Globulins Product Type and Application

Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 28. CSL Behring Company Information

Table 29. CSL Behring Description and Business Overview

Table 30. CSL Behring Hyperimmune Globulins Product

Table 31. CSL Behring Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 32. CSL Behring Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 33. CSL Behring Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 34. CSL Behring Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 35. CSL Behring Recent Developments

Table 36. Grifols Company Information

Table 37. Grifols Description and Business Overview

Table 38. Grifols Hyperimmune Globulins Product

Table 39. Grifols Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 40. Grifols Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 41. Grifols Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 42. Grifols Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 43. Grifols Recent Developments

Table 44. Biotest Company Information

Table 45. Biotest Description and Business Overview

Table 46. Biotest Hyperimmune Globulins Product

Table 47. Biotest Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 48. Biotest Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 49. Biotest Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 50. Biotest Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 51. Biotest Recent Developments

Table 52. Kedrion Company Information

Table 53. Kedrion Description and Business Overview

Table 54. Kedrion Hyperimmune Globulins Product

Table 55. Kedrion Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 56. Kedrion Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 57. Kedrion Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 58. Kedrion Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 59. Kedrion Recent Developments

Table 60. CBPO Company Information

Table 61. CBPO Description and Business Overview

Table 62. CBPO Hyperimmune Globulins Product

Table 63. CBPO Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 64. CBPO Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 65. CBPO Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 66. CBPO Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 67. CBPO Recent Developments

Table 68. Emergent (Cangene) Company Information

Table 69. Emergent (Cangene) Description and Business Overview

Table 70. Emergent (Cangene) Hyperimmune Globulins Product

Table 71. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 72. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 73. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 74. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 75. Emergent (Cangene) Recent Developments

Table 76. Kamada Company Information

Table 77. Kamada Description and Business Overview

Table 78. Kamada Hyperimmune Globulins Product

Table 79. Kamada Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 80. Kamada Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 81. Kamada Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 82. Kamada Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 83. Kamada Recent Developments

Table 84. CNBG Company Information

Table 85. CNBG Description and Business Overview

Table 86. CNBG Hyperimmune Globulins Product

Table 87. CNBG Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. CNBG Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 89. CNBG Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 90. CNBG Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 91. CNBG Recent Developments

Table 92. Hualan Bio Company Information

Table 93. Hualan Bio Description and Business Overview

Table 94. Hualan Bio Hyperimmune Globulins Product

Table 95. Hualan Bio Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 96. Hualan Bio Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 97. Hualan Bio Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 98. Hualan Bio Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 99. Hualan Bio Recent Developments

Table 100. Shanghai RAAS Company Information

Table 101. Shanghai RAAS Description and Business Overview

Table 102. Shanghai RAAS Hyperimmune Globulins Product

Table 103. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 104. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 105. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 106. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 107. Shanghai RAAS Recent Developments

Table 108. Sichuan Yuanda Shuyang Company Information

Table 109. Sichuan Yuanda Shuyang Description and Business Overview

Table 110. Sichuan Yuanda Shuyang Hyperimmune Globulins Product

Table 111. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 112. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 113. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 114. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 115. Sichuan Yuanda Shuyang Recent Developments

Table 116. ADMA Biologics Company Information

Table 117. ADMA Biologics Description and Business Overview

Table 118. ADMA Biologics Hyperimmune Globulins Product

Table 119. ADMA Biologics Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 120. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Product in 2024

Table 121. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Application in 2024

Table 122. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024

Table 123. ADMA Biologics Recent Developments

Table 124. North America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 125. North America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 126. North America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 127. North America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 128. North America Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)

Table 129. North America Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)

Table 130. Asia-Pacific Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)

Table 131. Asia-Pacific Hyperimmune Globulins Sales by Region (2026-2031) & (K Units)

Table 132. Asia-Pacific Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)

Table 133. Asia-Pacific Hyperimmune Globulins Revenue by Region (2026-2031) & (US$ Million)

Table 134. Asia-Pacific Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)

Table 135. Asia-Pacific Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)

Table 136. Europe Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 137. Europe Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 138. Europe Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 139. Europe Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 140. Europe Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)

Table 141. Europe Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)

Table 142. Latin America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 143. Latin America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 144. Latin America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 145. Latin America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 146. Latin America Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)

Table 147. Latin America Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)

Table 148. Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 149. Middle East and Africa Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 150. Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 151. Middle East and Africa Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 152. Middle East and Africa Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)

Table 153. Middle East and Africa Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)

Table 154. Hyperimmune Globulins Key Raw Materials, Industry Status and Trend

Table 155. Hyperimmune Globulins Key Raw Materials and Upstream Suppliers

Table 156. Hyperimmune Globulins Clients Status and Trend

Table 157. Hyperimmune Globulins Typical Clients

Table 158. Hyperimmune Globulins Distributors

Table 159. Hyperimmune Globulins Market Trends

Table 160. Hyperimmune Globulins Market Drivers

Table 161. Hyperimmune Globulins Market Challenges

Table 162. Hyperimmune Globulins Market Restraints

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

Table 166. QYR Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Hyperimmune Globulins Product Picture

Figure 2. Global Hyperimmune Globulins Market Size by Type (US$ Million): 2020 VS 2024 VS 2031

Figure 3. Global Hyperimmune Globulins Sales Market Share by Type in 2024 & 2031

Figure 4. Hepatitis B Immunoglobulins Product Picture

Figure 5. Rabies Immunoglobulins Product Picture

Figure 6. Tetanus Immunoglobulins Product Picture

Figure 7. Rho(D) Immunoglobulins Product Picture

Figure 8. Herpes Zoster Immune Globulin Product Picture

Figure 9. Other Product Picture

Figure 10. Global Hyperimmune Globulins Market Size by Application (US$ Million): 2020 VS 2024 VS 2031

Figure 11. Global Hyperimmune Globulins Sales Market Share by Application in 2024 & 2031

Figure 12. Government Institutions

Figure 13. Private Sector

Figure 14. Other

Figure 15. Hyperimmune Globulins Report Years Considered

Figure 16. Global Hyperimmune Globulins Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Hyperimmune Globulins Market Size 2020-2031 (US$ Million)

Figure 18. Global Hyperimmune Globulins Sales 2020-2031 (K Units)

Figure 19. Global Hyperimmune Globulins Sales Market Share Forecast by Region (2020-2031)

Figure 20. Global Hyperimmune Globulins Revenue Market Share by Region (2020-2031)

Figure 21. Global Hyperimmune Globulins Sales Market Share Forecast by Type (2020-2031)

Figure 22. Global Hyperimmune Globulins Revenue Market Share Forecast by Type (2020-2031)

Figure 23. Hyperimmune Globulins Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)

Figure 24. Global Hyperimmune Globulins Sales Market Share Forecast by Application (2020-2031)

Figure 25. Global Hyperimmune Globulins Revenue Market Share Forecast by Application (2020-2031)

Figure 26. Hyperimmune Globulins Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)

Figure 27. Hepatitis B Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031

Figure 28. Rabies Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031

Figure 29. Tetanus Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031

Figure 30. Rho(D) Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031

Figure 31. Herpes Zoster Immune Globulin of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031

Figure 32. Other of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031

Figure 33. Global Hyperimmune Globulins Sales Share by Manufacturer in 2024

Figure 34. Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 35. Hepatitis B Immunoglobulins Market Sales Proportion by Manufacturer in 2024

Figure 36. Rabies Immunoglobulins Market Sales Proportion by Manufacturer in 2024

Figure 37. Tetanus Immunoglobulins Market Sales Proportion by Manufacturer in 2024

Figure 38. Rho(D) Immunoglobulins Market Sales Proportion by Manufacturer in 2024

Figure 39. Herpes Zoster Immune Globulin Market Sales Proportion by Manufacturer in 2024

Figure 40. Other Market Sales Proportion by Manufacturer in 2024

Figure 41. North America Hyperimmune Globulins Revenue 2020-2031 (US$ Million)

Figure 42. North America Hyperimmune Globulins Sales Market Share by Type (2020-2025)

Figure 43. North America Hyperimmune Globulins Sales Market Share by Application (2020-2025)

Figure 44. Asia-Pacific Hyperimmune Globulins Revenue 2020-2031 (US$ Million)

Figure 45. Asia-Pacific Hyperimmune Globulins Sales Market Share by Region (2020-2031)

Figure 46. Asia-Pacific Hyperimmune Globulins Revenue Market Share by Region (2020-2031)

Figure 47. Asia-Pacific Hyperimmune Globulins Sales Market Share by Type (2020-2025)

Figure 48. Asia-Pacific Hyperimmune Globulins Sales Market Share by Application (2020-2025)

Figure 49. Europe Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)

Figure 50. Europe Hyperimmune Globulins Sales Market Share by Country (2020-2031)

Figure 51. Europe Hyperimmune Globulins Revenue Market Share by Country (2020-2031)

Figure 52. Europe Hyperimmune Globulins Sales Market Share by Type (2020-2025)

Figure 53. Europe Hyperimmune Globulins Sales Market Share by Application (2020-2025)

Figure 54. Latin America Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)

Figure 55. Latin America Hyperimmune Globulins Sales Market Share by Country (2020-2031)

Figure 56. Latin America Hyperimmune Globulins Revenue Market Share by Country (2020-2025)

Figure 57. Latin America Hyperimmune Globulins Sales Market Share by Type (2020-2025)

Figure 58. Latin America Hyperimmune Globulins Sales Market Share by Application (2020-2025)

Figure 59. Middle East and Africa Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)

Figure 60. Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2020-2031)

Figure 61. Middle East and Africa Hyperimmune Globulins Revenue Market Share by Country (2020-2031)

Figure 62. Middle East and Africa Hyperimmune Globulins Sales Market Share by Type (2020-2025)

Figure 63. Middle East and Africa Hyperimmune Globulins Sales Market Share by Application (2020-2025)

Figure 64. Hyperimmune Globulins Supply Chain (Upstream and Downstream Market)

Figure 65. Global Production Market Share of Hyperimmune Globulins Raw Materials by Region in 2024

Figure 66. Hyperimmune Globulins Distribution Channels

Figure 67. Global Hyperimmune Globulins Percentage 2020-2031: Indirect Sales VS Direct Sales

Figure 68. Global Hyperimmune Globulins Percentage 2020-2031: Online Sales VS Offline Sales

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Hyperimmune Globulins in 2025? zhanKai

The global market size of Hyperimmune Globulins in 2025 was 2058 Million USD.

Which companies rank high in the global Hyperimmune Globulins market? shouQi

What was the global market size of Hyperimmune Globulins in 2031? shouQi

What is the annual compound growth rate of the global Hyperimmune Globulins market size from 2025 to 2031? shouQi

Which region is expected to have the highest market share? shouQi

Related Reports

Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Hyperimmune Globulins market size was US$ 2058 million in 2025 and is forecast to reach a readjusted size of US$ 3284 million by 2032 with a CAGR of 7.0% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 91
USD 4250.00
(Single User License)
Global Hyperimmune Globulins Market Research Report 2026
The global Hyperimmune Globulins market was valued at US$ 2058 million in 2025 and is anticipated to reach US$ 3284 million by 2032, at a CAGR of 7.0% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 119
USD 2900.00
(Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Hyperimmune Globulins was estimated to be worth US$ 2058 million in 2025 and is projected to reach US$ 3284 million, growing at a CAGR of 7.0% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 115
USD 3950.00
(Single User License)
Global Hyperimmune Globulins Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Hyperimmune Globulins market is projected to grow from US$ 1936 million in 2024 to US$ 3089 million by 2031, at a CAGR of 7.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 164
USD 4900.00
(Single User License)
Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Hyperimmune Globulins market size was US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 95
USD 4250.00
(Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Hyperimmune Globulins was estimated to be worth US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 113
USD 3950.00
(Single User License)
Global Hyperimmune Globulins Market Research Report 2025
The global market for Hyperimmune Globulins was valued at US$ 1936 million in the year 2024 and is projected to reach a revised size of US$ 3089 million by 2031, growing at a CAGR of 7.0% during the forecast period.
Published Date: 2025-01-16
Pages: 97
USD 2900.00
(Single User License)
Global and Japan Hyperimmune Globulins Market Report & Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published Date: 2024-09-05
Pages: 128
USD 4350.00
(Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published Date: 2024-09-05
Pages: 129
USD 3950.00
(Single User License)
Global Hyperimmune Globulins Market Insights, Forecast to 2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published Date: 2024-09-05
Pages: 160
USD 4900.00
(Single User License)

Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Hyperimmune Globulins market size was US$ 2058 million in 2025 and is forecast to reach a readjusted size of US$ 3284 million by 2032 with a CAGR of 7.0% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 91
USD 4250.00 (Single User License)
Global Hyperimmune Globulins Market Research Report 2026
The global Hyperimmune Globulins market was valued at US$ 2058 million in 2025 and is anticipated to reach US$ 3284 million by 2032, at a CAGR of 7.0% from 2026 to 2032.
Published: 2026-01-04
Pages: 119
USD 2900.00 (Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Hyperimmune Globulins was estimated to be worth US$ 2058 million in 2025 and is projected to reach US$ 3284 million, growing at a CAGR of 7.0% from 2026 to 2032.
Published: 2026-01-04
Pages: 115
USD 3950.00 (Single User License)
Global Hyperimmune Globulins Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Hyperimmune Globulins market is projected to grow from US$ 1936 million in 2024 to US$ 3089 million by 2031, at a CAGR of 7.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 164
USD 4900.00 (Single User License)
Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Hyperimmune Globulins market size was US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 95
USD 4250.00 (Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Hyperimmune Globulins was estimated to be worth US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 113
USD 3950.00 (Single User License)
Global Hyperimmune Globulins Market Research Report 2025
The global market for Hyperimmune Globulins was valued at US$ 1936 million in the year 2024 and is projected to reach a revised size of US$ 3089 million by 2031, growing at a CAGR of 7.0% during the forecast period.
Published: 2025-01-16
Pages: 97
USD 2900.00 (Single User License)
Global and Japan Hyperimmune Globulins Market Report & Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published: 2024-09-05
Pages: 128
USD 4350.00 (Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published: 2024-09-05
Pages: 129
USD 3950.00 (Single User License)
Global Hyperimmune Globulins Market Insights, Forecast to 2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published: 2024-09-05
Pages: 160
USD 4900.00 (Single User License)